The estimated Net Worth of Michael Kowolenko is at least $8.8 Milion dollars as of 25 July 2007. Michael Kowolenko owns over 20,507 units of Biogen Inc stock worth over $7,690,847 and over the last 19 years Michael sold BIIB stock worth over $1,112,451.
Sign up
Michael Kowolenko BIIB stock SEC Form 4 insiders trading
Michael has made over 5 trades of the Biogen Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently Michael exercised 20,507 units of BIIB stock worth $864,165 on 25 July 2007.
The largest trade Michael's ever made was exercising 20,507 units of Biogen Inc stock on 25 July 2007 worth over $864,165. On average, Michael trades about 5,507 units every 34 days since 2006. As of 25 July 2007 Michael still owns at least 38,630 units of Biogen Inc stock.
You can see the complete history of Michael Kowolenko stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Michael Kowolenko's mailing address?
Michael's mailing address filed with the SEC is 14 CAMBRIDGE CENTER, , CAMBRIDGE, MA, 02142.
Insiders trading at Biogen Inc
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner a Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
What does Biogen Inc do?
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
What does Biogen Inc's logo look like?
Complete history of Michael Kowolenko stock trades at Biogen Inc
Biogen Inc executives and stock owners
Biogen Inc executives and other stock owners filed with the SEC include:
-
Michel Vounatsos,
Chief Executive Officer, Director -
Susan Alexander,
Executive Vice President, Chief Legal Officer and Secretary -
Alfred Sandrock,
Executive Vice President, Research and Development, Chief Medical Officer -
Chirfi Guindo,
Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation -
Michel Vounatsos,
CEO & Director -
Susan H. Alexander Esq.,
Exec. VP, Chief Legal Officer & Sec. -
Susan H. Alexander,
Exec. VP, Chief Legal Officer & Sec. -
Michael R. McDonnell,
Exec. VP & CFO -
Chirfi Guindo,
Exec. VP of Global Product Strategy & Commercialization -
Stelios Papadopoulos,
Independent Chairman of the Board -
Robert Pangia,
Independent Director -
Brian Posner,
Independent Director -
Alexander Denner,
Independent Director -
Nancy Leaming,
Independent Director -
Caroline Dorsa,
Independent Director -
Stephen Sherwin,
Independent Director -
Eric Rowinsky,
Independent Director -
Richard Mulligan,
Independent Director -
Jesus Mantas,
Independent Director -
William Hawkins,
Independent Director -
Robin Kramer,
Chief Accounting Officer, Vice President -
Daniel Karp,
Executive Vice President, Corporate Development -
Alphonse Galdes,
Executive Vice President, Pharmaceutical Operations and Technology -
Ginger Gregory,
Chief Human Resource Officer, Executive Vice President -
Michael McDonnell,
Chief Financial Officer, Executive Vice President -
Dr. Sanjay Jariwala,
Sr. VP of Worldwide Medical -
Nicole Murphy,
Head of Pharmaceutical Operations & Technology -
Dr. Anabella Villalobos Ph.D.,
Sr. VP of Biotherapeutic & Medicinal Sciences -
Dr. Alphonse Galdes,
Exec. VP of Pharmaceutical Operations & Technology -
Dr. Ginger Gregory,
Exec. VP & Chief HR Officer -
Natacha Gassenbach,
Chief Communication Officer & Head of Corp. Affairs -
Michael Hencke,
Director of Investor Relations -
Mark J. Hernon,
Sr. VP & Chief Information Officer -
Robin C. Kramer,
Sr. VP & Chief Accounting Officer -
George A Scangos,
Chief Executive Officer -
Adriana Karaboutis,
EVP, Tech. and Bus. Solutions -
Michael D Ehlers,
EVP, Research and Development -
Gregory F Covino,
VP, Chief Accounting Officer -
Lynn Schenk,
Director -
Paul Mc Kenzie,
EVP Pharmaceutical Oper & Tech -
Paul J Clancy,
CFO -
Kenneth Di Pietro,
EVP Human Resources -
Adam Koppel,
SVP, Chief Strategy Officer -
Susan Langer,
Director -
Jean Paul Kress,
EVP Pres Int'l & Global Hd GTO -
Priya Singhal,
Head of Development -
Jeffrey D Capello,
EVP & Chief Financial Officer -
Monish D Patolawala,
Director -
Phillip A Sharp,
Director -
Steven H Holtzman,
EVP Corp Devel and Strategy -
John Cox,
EVP Pharmaceutical Oper & Tech -
Spyridon Artavanis Tsakonas,
SVP, Chief Scientific Officer -
William Young,
Director -
Raymond Pawlicki,
SVP, Chief Information Officer -
Stuart A Kingsley,
EVP, Global Comm. Operations -
Douglas E Williams,
EVP Research & Development -
Craig Eric Schneier,
EVP, Human Resources -
Robert E. Gagnon,
Chief Acct Officer VP & Contr -
Francesco Granata,
EVP Global Commercial Operatio -
James C Mullen,
CEO and President -
Michael F Mac Lean,
SVP, Chief Accounting Officer -
Bruce Ross,
Director -
Robert A Hamm,
SVP, Immunology Business Unit -
Cecil B Pickett,
President, R & D -
Marijn E Dekkers,
Director -
Lawrence C Best,
Director -
Faheem Hasnain,
SVP, Oncology SBU -
Hans Peter Hasler,
SVP, International -
Mark C Wiggins,
EVP - Business Development -
Michael Lytton,
EVP Corporate & Business Devel -
Alan Glassberg,
Director -
John Michael Dunn,
EVP - New Ventures -
Michael Gilman,
EVP - Research -
Thomas J Bucknum,
EVP. General Counsel, Sec. -
Nabil Hanna,
EVP, Research -
William H Rastetter,
Executive Chairman -
William R Rohn,
Exec VP & COO -
Sylvie L Gregoire,
EVP, Bus. Dev & Program Mgmt. -
Burt A Adelman,
EVP, Development -
Alan Belzer,
Director -
Michael Kowolenko,
SVP, Pharm Ops & Technology -
Peter N Kellogg,
Executive Vice President, CFO -
Mary L Good,
Director -
Thomas F Keller,
Director -
Connie Matsui,
Sr V P, Planning& Resource Dev -
Christopher Viehbacher,
President and CEO -
Maria C Freire,
Director -
William D /Ca/ Jones,
Director -
Nicole Murphy,
Head of Pharm Ops and Tech -
Rachid Izzar,
Head of Global Product Strat. -
Adam Keeney,
Head of Corporate Development -
Jane Grogan,
Head of Research